Guidance on letter drafting for marketing authorisation holders
Updated 4 April 2023
漏 Crown copyright 2023
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected].
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at /government/publications/how-to-draft-a-direct-healthcare-professional-communication/guidance-on-letter-drafting-for-marketing-authorisation-holders
1. Introduction
A direct healthcare professional communication (DHPC) aims to ensure safe and effective use of a marketed medicine. Letters are sent directly to healthcare professionals by marketing authorisation holders or by the licensing authority.
Direct healthcare professional communications should not include any material that might constitute advertising or be considered promotional or commercial.
2. Guidance for marketing authorisation holders
provides guidance to marketing authorisation holders on how to communicate and coordinate safety information concerning medicinal products authorised in the UK, including via direct healthcare professional communications. In addition, GVP Annex II includes templates for direct healthcare professional communications and communication plans, which should be used for UK authorised products.
UK-specific requirements in relation to the dissemination of DHPCs are outlined in a UK statutory guidance note.
Irrespective of the licensing route for a UK authorised product, marketing authorisation holders should submit both the draft and finalised versions of DHPCs and communication plans to the MHRA via [email protected] and should wait until comments are received before disseminating in the UK.
3. Call for reporting
All UK direct healthcare professional communication letters should always include a 鈥楥all for reporting鈥� section to outline national arrangements for reporting suspected adverse drug reactions.
The Template 鈥楥all for Reporting鈥� sections for UK letters should be used to encourage reporting to the Yellow Card scheme. Additional text should be considered for medicines subject to additional monitoring and for biological/biosimilar medicines and vaccines.